Zobrazeno 1 - 10
of 59
pro vyhledávání: '"C, Tzallas"'
Autor:
M. Kastrisiou, G. Zarkavelis, A. Kougioumtzi, C. Tzallas, E. Tselikou, A. Mantziou, K. Gkrepi, E. Fountzilas, G. Nasioulas, A. Batistatou, A. Magklara, G. Pentheroudakis
Publikováno v:
Annals of Oncology. 32:S158-S159
Autor:
M. Kastrisiou, Anna Goussia, Georgios Pentheroudakis, Angeliki Magklara, K. Gkrepi, C. Tzallas, A. Kougioumtzi, A. Christopoulou, S. Gkoura
Publikováno v:
Annals of Oncology. 31:S149
Autor:
M. Kastrisiou, A. Batistatou, E. Tselikou, C. Tzallas, Eirini Papadopoulou, Georgios Zarkavelis, A. Mantziou, Angeliki Magklara, Georgios Pentheroudakis, G. Nasioulas
Publikováno v:
Annals of Oncology. 31:S176
Autor:
M. Kastrisiou, G. Nasioulas, C. Tzallas, Georgios Pentheroudakis, Angeliki Magklara, Emmanouil Saloustros, Anastasia Kougioumtzi, Athanasios Kotsakis, Anna Batistatou, Eirini Papadopoulou, Georgios Zarkavelis
Publikováno v:
Annals of Oncology. 30:vii13
Background Metastatic colorectal cancer (mCRC) affects 20% of patients diagnosed with colorectal malignancy and is a major cause of cancer-related death worldwide. Epidermal growth factor receptor (EGFR) blockade with monoclonal antibodies, in combin
Autor:
C. Tzallas, Anastasia Kougioumtzi, Anna Goussia, Georgios Pentheroudakis, M. Kastrisiou, K. Gkrepi, Angeliki Magklara, S. Gkoura
Publikováno v:
Annals of Oncology. 30:vii12
Background Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis and high mortality worldwide. Despite the emergence of new therapeutic approaches for the treatment of inoperable PDAC, reliable prognostic/predictive biomarkers are
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Long-Term Treatment With EPO Increases Serum Levels of High-Density Lipoprotein in Patients With CKD
Autor:
Eleni C. Papavasiliou, Peter Nikolopoulos, C. Tzallas, Konstantinos P. Katopodis, Kostas C. Siamopoulos, Chariklia Gouva, Alexandros D. Tselepis
Publikováno v:
American Journal of Kidney Diseases. 48:242-249
Among lipid abnormalities observed in patients with chronic kidney disease (CKD) is a significant decrease in serum high-density lipoprotein cholesterol (HDL-C) levels. In a previously published randomized control trial, we showed that early erythrop
Autor:
Eleni Bairaktari, M. Kalientzidou, Konstantin Seferiadis, Alexandros D. Tselepis, C. Tzallas, Moses Elisaf, Kostas C. Siamopoulos
Publikováno v:
Clinical Biochemistry. 37:937-940
Objectives: To evaluate alternative equations for the estimation of low-density lipoprotein cholesterol (LDL-C) than the Friedewald equation in hemodialysis patients. Design and methods: The equations LDL-C = 0.41TC − 0.14TG + 0.66ApoB − 10.43 an
Autor:
Sonia Anna Karabina, Orestes Tsolas, Moses Elisaf, Kostas C. Siamopoulos, Eleni Bairaktari, C. Tzallas, Alexandros D. Tselepis
Publikováno v:
Clinical Biochemistry. 34:593-602
Objectives: Current recommendations for the management of dyslipidemia are largely based on the concentration of LDL-C. Most clinical laboratories estimate the concentration of LDL-C by the recommended routine method, the equation of Friedewald, in s
Autor:
Alexandros A. Drosos, Konstantinos L. Bourantas, Eleftheria Hatzimichael, Paraskevi V. Voulgari, C. Tzallas, Stavroula Tsiara
Publikováno v:
European Journal of Haematology. 66:31-36
Objectives: Recombinant human erythropoietin (rHuEpo) improves anemia in 25% of patients with myelodysplastic syndromes (MDS). The variable and sometimes low response rate to rHuEpo treatment raises the question whether the existence of autoantibodie